These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 18250228)

  • 1. CYP4F2 genetic variant alters required warfarin dose.
    Caldwell MD; Awad T; Johnson JA; Gage BF; Falkowski M; Gardina P; Hubbard J; Turpaz Y; Langaee TY; Eby C; King CR; Brower A; Schmelzer JR; Glurich I; Vidaillet HJ; Yale SH; Qi Zhang K; Berg RL; Burmester JK
    Blood; 2008 Apr; 111(8):4106-12. PubMed ID: 18250228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.
    Singh O; Sandanaraj E; Subramanian K; Lee LH; Chowbay B
    Drug Metab Pharmacokinet; 2011; 26(2):130-6. PubMed ID: 21084764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
    Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
    Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
    McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
    Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.
    Lee KE; Chang BC; Kim HO; Yoon IK; Lee NR; Park HY; Gwak HS
    Ther Drug Monit; 2012 Jun; 34(3):275-82. PubMed ID: 22549502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
    Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA
    Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.
    Li JH; Ma GG; Zhu SQ; Yan H; Wu YB; Xu JJ
    J Cardiothorac Surg; 2012 Sep; 7():97. PubMed ID: 23013706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of cytochrome 4F2 rs2108622 genetic variant and its effects on the lipid profile and complications of type II diabetes among a sample of patients in Jordan: A pilot study.
    Jarrar Y; Alkhalili M; Alhawari H; Abaalkhail SJ; Alkhalili S; Alhawari H; Momani M; Obeidat AN; Fram RK
    Prostaglandins Other Lipid Mediat; 2023 Apr; 165():106715. PubMed ID: 36758722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the
    Sun X; Yu WY; Ma WL; Huang LH; Yang GP
    Biomed Rep; 2016 Apr; 4(4):498-506. PubMed ID: 27073641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
    Zhang JE; Jorgensen AL; Alfirevic A; Williamson PR; Toh CH; Park BK; Pirmohamed M
    Pharmacogenet Genomics; 2009 Oct; 19(10):781-9. PubMed ID: 19741565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.
    Perini JA; Struchiner CJ; Silva-Assunção E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2010 Apr; 87(4):417-20. PubMed ID: 20182420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.
    Kocael A; Eronat AP; Tüzüner MB; Ekmekçi A; Orhan AL; İkizceli İ; Yılmaz-Aydoğan H; Öztürk O
    Mol Biol Rep; 2019 Apr; 46(2):1825-1833. PubMed ID: 30712247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.
    Athinarayanan S; Wei R; Zhang M; Bai S; Traber MG; Yates K; Cummings OW; Molleston J; Liu W; Chalasani N
    PLoS One; 2014; 9(4):e95366. PubMed ID: 24759732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.